- Home
- ESRT vs ZYME Comparison
ESRT vs ZYME Comparison
Compare ESRT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- ZYME
- Stock Information
- Founded
- ESRT 2011
- ZYME 2003
- Country
- ESRT United States
- ZYME United States
- Employees
- ESRT N/A
- ZYME N/A
- Industry
- ESRT Real Estate Investment Trusts
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- ZYME Health Care
- Exchange
- ESRT Nasdaq
- ZYME Nasdaq
- Market Cap
- ESRT 1.2B
- ZYME 1.2B
- IPO Year
- ESRT 2013
- ZYME 2017
- Fundamental
- Price
- ESRT $7.22
- ZYME $18.04
- Analyst Decision
- ESRT Hold
- ZYME Buy
- Analyst Count
- ESRT 2
- ZYME 7
- Target Price
- ESRT $10.65
- ZYME $20.00
- AVG Volume (30 Days)
- ESRT 1.6M
- ZYME 651.8K
- Earning Date
- ESRT 10-29-2025
- ZYME 10-30-2025
- Dividend Yield
- ESRT 1.91%
- ZYME N/A
- EPS Growth
- ESRT N/A
- ZYME N/A
- EPS
- ESRT 0.24
- ZYME N/A
- Revenue
- ESRT $763,746,000.00
- ZYME $122,867,000.00
- Revenue This Year
- ESRT $2.27
- ZYME $107.76
- Revenue Next Year
- ESRT $3.04
- ZYME $2.35
- P/E Ratio
- ESRT $30.60
- ZYME N/A
- Revenue Growth
- ESRT 1.14
- ZYME 95.94
- 52 Week Low
- ESRT $6.56
- ZYME $9.03
- 52 Week High
- ESRT $11.62
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- ESRT 34.94
- ZYME 73.32
- Support Level
- ESRT $7.72
- ZYME $16.20
- Resistance Level
- ESRT $7.88
- ZYME $17.40
- Average True Range (ATR)
- ESRT 0.17
- ZYME 0.56
- MACD
- ESRT -0.04
- ZYME 0.00
- Stochastic Oscillator
- ESRT 4.44
- ZYME 91.70
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.